<p>Microtubule targeting agents are commonly prescribed for early and metastatic breast cancer and other solid tumors. However, interindividual variability in microtubule targeting drug response and toxicity can cause limited therapeutic benefit and impact quality of life. In the present study, genome-wide analyses were performed to investigate how genetic factors can be used to increase prediction of treatment response and toxicity, identify genes or gene pathways associated with chemotherapy-induced neurotoxicity, and inform further in vitro studies that may help isolate differences in response and toxicity of microtubule targeting agents.</p>

Pharmacogenomic Analysis of Microtubule Targeting Agent Response and    Toxicity

Peripheral Nervous System Diseases study with SNP Genotypes (Array), SNP/CNV Genotypes (NGS) data on dbGaP (624 participants)

Pharmacogenomic Analysis of Microtubule Targeting Agent Response and Toxicity

Description

Applying For Access

Summary